{"id":"arotinolol","rwe":[],"tags":[{"label":"arotinolol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["arotinolol","arotinolol hydrochloride","arotinolol HCl"],"offLabel":[],"synonyms":["arotinolol","arotinolol hydrochloride","arotinolol HCl"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"arotinolol","explanation":"Think of it like a key fitting into a lock. Arotinolol is a key that blocks the action of certain enzymes, which are like locks that control various bodily functions. By blocking these enzymes, arotinolol can help to slow down or stop certain processes in the body.","oneSentence":"Arotinolol works by blocking the action of certain enzymes in the body.","technicalDetail":"Arotinolol is a beta-adrenergic receptor blocker that inhibits the activity of beta-adrenergic receptors, which are G protein-coupled receptors that play a key role in regulating various physiological processes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/243","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AROTINOLOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AROTINOLOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:45:37.023966","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:52:38.678640+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"arotinolol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":["Chronic Kidney Disease(CKD)","Nocturnal Hypertension"],"enrollment":200,"completionDate":"2028-12-31"},{"nctId":"NCT02612298","phase":"PHASE4","title":"Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2015-08","conditions":["Essential Hypertension"],"enrollment":198,"completionDate":"2018-09-13"},{"nctId":"NCT01351636","phase":"PHASE4","title":"Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2011-04","conditions":["Chronic Kidney Disease"],"enrollment":300,"completionDate":"2018-10-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008153","UNII":"394E3P3B99","CHEBI":"CHEBI:31239","INN_ID":"5215","UMLSCUI":"C0104221","ChEMBL_ID":"CHEMBL93298","KEGG_DRUG":"D07465","DRUGBANK_ID":"DB09204","PUBCHEM_CID":"2239","SECONDARY_CAS_RN":"68377-91-3","MESH_SUPPLEMENTAL_RECORD_UI":"C024523"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":90,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"AROTINOLOL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arotinolol is a small molecule used in the treatment of essential hypertension, chronic kidney disease, nocturnal hypertension, and chronic kidney disease. It is administered as a hydrochloride and has been studied in clinical trials for its efficacy and safety in lowering morning blood pressure and heart rate.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:52:38.678640+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}